Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca and Lilly to team Cyramza with anti-PD-L1

This article was originally published in Scrip

Executive Summary

AstraZeneca and Eli Lilly have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Lilly's VEGF receptor 2 inhibitor Cyramza (ramucirumab) in a Phase I study advanced solid tumors. The alliance is one of a growing number looking at combining immune-oncology products with other more established targeted anticancers. "The development of immune checkpoint inhibitors has been one of the more exciting research advancements in recent oncology history, but it is going to be even more interesting to see how these inhibitors can be combined with other proven targeted therapies," said Dr Richard Gaynor senior vice-president, product development and medical affairs at Lilly Oncology. "This collaboration represents the next wave of immuno-oncology research by bringing together two innovative medicines."

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028865

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel